Clinical Trial Update: Effect of MD1003 in Amyotrophic Lateral Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for MD1003 in amyotrophic lateral sclerosis (ALS) has completed recruitment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• MD1003 (biotin (high-dose))

Snippet

Sponsor: MedDay Pharmaceuticals SA | Conditions: ALS, Amyotrophic Lateral Sclerosis | Phase 2 | Status: COMPLETED